Flomics Biotech

Startup
  • Location

    Hall 8.0 – 4YFN & Partner District Stand 8.0B10

Information

Flomics Biotech is a pioneering startup that aims to transform early cancer detection by developing a minimally invasive test based on cfRNA-based liquid biopsy. Our lead product, Sentinel, identifies five of the deadliest types of cancer—lung, colorectal, pancreatic, prostate, and breast—from a single blood sample, even at Stage I. Unlike ctDNA tests, our cfRNA biomarkers capture real-time gene expression, enabling highly sensitive, tissue-specific diagnostics. With 81% sensitivity and 90% specificity, Sentinel outperforms current solutions and supports timely, personalized interventions. Powered by an AI-driven bioinformatics platform, Flomics is setting a new standard in scalable, minimally invasive cancer diagnostics.

Key Information

  • Growth Stage
    Series A
  • Country
    Spain
  • Founding Year
    2018